A synthetic heptapeptide derived from the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro C-terminal extension for metabolic stability. Developed alongside Semax at the Institute of Molecular Genetics (Russian Academy of Sciences), Selank modulates GABA-A receptor activity, reduces enkephalin degradation, and stabilizes enkephalin blood levels. Approved in Russia as an anxiolytic since 2008.
Research FocusAnxiolysis, immune modulation, GABA-ergic signaling, cognitive performance under stress
ReconstitutionNormal saline (0.9% NaCl) for intranasal delivery
Stability14 days at 2–8°C reconstituted
Key distinction: Dual anxiolytic-immunomodulatory peptide — combines tuftsin-derived immune activity with GABA-ergic anxiolysis in a single molecule. Russian regulatory approval since 2008.
Scientific Evidence
Published Research
[1]
Kozlovskii II, Danchev ND. The optimizing action of the synthetic peptide selank on a conditioned active avoidance reflex. Neurosci Behav Physiol 2003;33:639-643 — PubMed 14552529
[2]
Zozulya AA et al. The inhibitory effect of Selank on enkephalin-degrading enzymes. Bull Exp Biol Med 2001;131:315-317 — PubMed 11550013
Research Use Only. All products sold by Lumen Peppers are intended solely for in vitro research and laboratory purposes. They are not drugs, supplements, or foods. Nothing on this page constitutes medical advice. Researchers are responsible for compliance with all applicable regulations. Last updated: April 14, 2026.